WallStSmart

Autolus Therapeutics Ltd (AUTL)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Autolus Therapeutics Ltd generates 45% more annual revenue ($1.08M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. AUTL earns a higher WallStSmart Score of 29/100 (F).

AUTL

Avoid

29

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 6.7Quality: 5.0
Piotroski: 3/9Altman Z: -3.63

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AUTLUndervalued (+55.5%)

Margin of Safety

+55.5%

Fair Value

$3.21

Current Price

$1.88

$1.33 discount

UndervaluedFair: $3.21Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AUTL2 strengths · Avg: 10.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
83655.0%10/10

Revenue surging 83655.0% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

AUTL4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$500.39M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Debt/EquityHealth
1.123/10

Elevated debt levels

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.9x4/10

Trading at 16.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : AUTL

The strongest argument for AUTL centers on Price/Book, Revenue Growth. Revenue growth of 83655.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : AUTL

The primary concerns for AUTL are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

AUTL profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

AUTL carries more volatility with a beta of 2.00 — expect wider price swings.

AUTL is growing revenue faster at 83655.0% — sustainability is the question.

AUTL generates stronger free cash flow (-26M), providing more financial flexibility.

Bottom Line

AUTL scores higher overall (29/100 vs 24/100) and 83655.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Autolus Therapeutics Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?